CHF Solutions to Host Clinician Webinar on Use of Ultrafiltration for Volume Management in Patients Treated for COVID-19
March 13 2020 - 8:00AM
CHF Solutions (Nasdaq: CHFS) today announced the company will host
an interactive, physician-led webinar to discuss the importance of
volume management in the treatment of patients with COVID-19.
Dr. Amir Kazory will moderate the discussion on March 17 at
11 AM EDT, which will include the role of ultrafiltration in
restoring and maintaining fluid balance in critically ill patients.
Dr. Mehdi Oloomi will discuss the importance of identifying
volume overload in COVID-19 patients and will be followed by Dr.
Maria DeVita who will cover role of congestion in the deterioration
of renal function. The panel will then discuss advantages of
ultrafiltration with the FDA-cleared Aquadex SmartFlow™. The
Aquadex SmartFlow system is a clinically proven therapy that
provides a simple, flexible, and smart method of removing excess
fluid from patients suffering from hypervolemia (volume
overload). The World Health Organization (WHO) recently
released a protocol for treating patients infected with the
coronavirus COVID-19, highlighting the need for effective fluid
management treatment strategies when caring for the critical
patient population because the risk of volume overload is very
high.1
Webinar Details: Presenters
Amir Kazory, MD, FASN, University of FloridaMaria DeVita, MD,
FACP, FASN, The Lennox Hill HospitalMehdi Oloomi, MD, The Mount
Sinai Hospital
Learning Objectives:
- Discuss the WHO protocol and the importance of identifying
volume overload in COVID-19 infected patients
- Understand the risks associated with volume overload,
importance of maintaining fluid balance, and benefits of using
ultrafiltration in patients with volume overload
- Discuss training and personnel required to quickly implement
access to ultrafiltration
- Hear real-world critical care patient case studies
“It’s important that health care providers are aware of
available, innovative technologies that can improve outcomes for
their patients,” said Dr. Amir Kazory, MD, FASN, University of
Florida. “Efficient volume management techniques are critical to
improving outcomes and quality of life in critically ill patients.
It's our responsibility as practicing physicians to understand how
we can aggressively treat and protect against adverse
outcomes.”
“With potential surges in critically ill patients as a result of
the COVID-19 pandemic, we want to ensure that clinicians understand
and have access to our products, teams and advisors,” said John
Erb, CEO of CHF Solutions. "We designed the Aquadex SmartFlow
system to address the needs of critical care patients suffering
from hypervolemia (volume overload) and want to ensure all patients
are able to access the care they need.”
Register to participate in this informative webinar by following
this link: www.bit.ly/2vhRW7z. For those unable to attend the
webinar, an audio archive of the webcast and a transcript will be
available at http://ir.chf-solutions.com/events within 48 hours
after the event concludes.
About CHF Solutions CHF Solutions, Inc.
(Nasdaq: CHFS) is a medical device company dedicated to improving
the lives of patients suffering from fluid overload with its novel
ultrafiltration therapy system. The company is focused on
developing, manufacturing and commercializing the Aquadex SmartFlow
system for ultrafiltration therapy. CHF Solutions is headquartered
in Minneapolis, Minn., with wholly-owned subsidiaries in Australia
and Ireland. The company has been listed on the Nasdaq Capital
Market since February 2012.
About the Aquadex SmartFlow System The Aquadex
SmartFlow system delivers clinically proven therapy using a simple,
flexible and smart method of removing excess fluid from patients
suffering from hypervolemia (fluid overload). The Aquadex SmartFlow
system is indicated for temporary (up to 8 hours) or extended
(longer than 8 hours in patients who require hospitalization) use
in adult and pediatric patients weighing 20 kg or more whose fluid
overload is unresponsive to medical management, including
diuretics. All treatments must be administered by a health care
provider, within an outpatient or inpatient clinical setting, under
physician prescription, both having received training in
extracorporeal therapies.
Forward-Looking Statements Certain statements
in this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements about the clinical
use of the Aquadex SmartFlow system in patients infected with the
coronavirus COVID-19. Forward-looking statements are predictions,
projections and other statements about future events that are based
on current expectations and assumptions and, as a result, are
subject to risks and uncertainties. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this release, including, without limitation, those
risk associated with our ability to execute on our commercial
strategy, the possibility that we may be unable to raise sufficient
funds necessary for our anticipated operations, our post-market
clinical data collection activities, benefits of our products to
patients, our expectations with respect to product development and
commercialization efforts, our ability to increase market and
physician acceptance of our products, potentially competitive
product offerings, intellectual property protection, our ability to
integrate acquired businesses, our expectations regarding
anticipated synergies with and benefits from acquired businesses,
and other risks and uncertainties described in our filings with the
SEC. Forward-looking statements speak only as of the date when
made. CHF Solutions does not assume any obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
________________________________________1 WHO reference number:
WHO/nCoV/Clinical/2020.3
CONTACTS
INVESTORS: Claudia Napal Drayton Chief
Financial Officer, CHF Solutions, Inc.
952-345-4205ir@chf-solutions.com
MEDIA: Brad
PerrielloHealth+Commerce617-817-1385brad@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024